Clinical and molecular characterization of patients with adenylosuccinate lyase deficiency.
Adenylosuccinate lyase deficiency
Epilepsy
Exome sequencing
Intellectual disability
Neurometabolic disease
Purine nucleotide cycle defect
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
25
08
2020
accepted:
03
02
2021
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Adenylosuccinate lyase deficiency (ADSLD) is an ultrarare neurometabolic recessive disorder caused by loss-of-function mutations in the ADSL gene. The disease is characterized by wide clinical variability. Here we provide an updated clinical profiling of the disorder and discuss genotype-phenotype correlations. Data were collected through "Our Journey with ADSL deficiency Association" by using a dedicated web survey filled-in by parents. Clinical and molecular data were collected from 18 patients (12 males, median age 10.9 years ± 7.3), from 13 unrelated families. The age at onset ranged from birth to the first three years (median age 0.63 years ± 0.84 SD), and age at diagnosis varied from 2 months to 17 years, (median age 6.4 years ± 6.1 SD). The first sign was a psychomotor delay in 8/18 patients, epilepsy in 3/18, psychomotor delay and epilepsy in 3/18, and apneas, hypotonia, nystagmus in single cases. One patient (sibling of a previously diagnosed child) had a presymptomatic diagnosis. The diagnosis was made by exome sequencing in 7/18 patients. All patients were definitively diagnosed with ADSL deficiency based on pathogenic variants and/or biochemical assessment. One patient had a fatal neonatal form of ADSL deficiency, seven showed features fitting type I, and nine were characterized by a milder condition (type II), with two showing a very mild phenotype. Eighteen different variants were distributed along the entire ADSL coding sequence and were predicted to have a variable structural impact by impairing proper homotetramerization or catalytic activity of the enzyme. Six variants had not previously been reported. All but two variants were missense. The study adds more details on the spectrum of ADSLD patients' phenotypes and molecular data.
Sections du résumé
BACKGROUND
Adenylosuccinate lyase deficiency (ADSLD) is an ultrarare neurometabolic recessive disorder caused by loss-of-function mutations in the ADSL gene. The disease is characterized by wide clinical variability. Here we provide an updated clinical profiling of the disorder and discuss genotype-phenotype correlations.
RESULTS
Data were collected through "Our Journey with ADSL deficiency Association" by using a dedicated web survey filled-in by parents. Clinical and molecular data were collected from 18 patients (12 males, median age 10.9 years ± 7.3), from 13 unrelated families. The age at onset ranged from birth to the first three years (median age 0.63 years ± 0.84 SD), and age at diagnosis varied from 2 months to 17 years, (median age 6.4 years ± 6.1 SD). The first sign was a psychomotor delay in 8/18 patients, epilepsy in 3/18, psychomotor delay and epilepsy in 3/18, and apneas, hypotonia, nystagmus in single cases. One patient (sibling of a previously diagnosed child) had a presymptomatic diagnosis. The diagnosis was made by exome sequencing in 7/18 patients. All patients were definitively diagnosed with ADSL deficiency based on pathogenic variants and/or biochemical assessment. One patient had a fatal neonatal form of ADSL deficiency, seven showed features fitting type I, and nine were characterized by a milder condition (type II), with two showing a very mild phenotype. Eighteen different variants were distributed along the entire ADSL coding sequence and were predicted to have a variable structural impact by impairing proper homotetramerization or catalytic activity of the enzyme. Six variants had not previously been reported. All but two variants were missense.
CONCLUSIONS
The study adds more details on the spectrum of ADSLD patients' phenotypes and molecular data.
Identifiants
pubmed: 33648541
doi: 10.1186/s13023-021-01731-6
pii: 10.1186/s13023-021-01731-6
pmc: PMC7919308
doi:
Substances chimiques
Adenylosuccinate Lyase
EC 4.3.2.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112Références
Eur J Paediatr Neurol. 2012 Jul;16(4):343-8
pubmed: 21903433
Lancet. 1984 Nov 10;2(8411):1058-61
pubmed: 6150139
JAMA. 2014 Nov 12;312(18):1870-9
pubmed: 25326635
J Child Neurol. 2001 May;16(5):301-8
pubmed: 11392513
Ital J Pediatr. 2017 Aug 2;43(1):65
pubmed: 28768552
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Neuropediatrics. 2002 Aug;33(4):186-9
pubmed: 12368987
Adv Exp Med Biol. 1998;431:177-80
pubmed: 9598054
Mol Genet Metab. 2008 Aug;94(4):435-42
pubmed: 18524658
Mol Genet Metab Rep. 2016 Jul 27;8:61-6
pubmed: 27504266
N Engl J Med. 2013 Oct 17;369(16):1502-11
pubmed: 24088041
Pediatr Neurol. 2010 Nov;43(5):351-4
pubmed: 20933180
Cytogenet Cell Genet. 1993;64(3-4):201-3
pubmed: 8404037
Neuropediatrics. 2014 Feb;45(1):50-5
pubmed: 23504561
J Inherit Metab Dis. 2008 Dec;31 Suppl 2:S329-32
pubmed: 18649008
Hum Mutat. 1999;13(3):197-202
pubmed: 10090474
Eur J Pediatr. 2012 Jan;171(1):131-8
pubmed: 21625931
Cytogenet Cell Genet. 1987;44(2-3):142-7
pubmed: 3568763
Biochemistry. 2002 Feb 19;41(7):2217-26
pubmed: 11841213
Hum Mol Genet. 2000 Sep 1;9(14):2159-65
pubmed: 10958654
Neuropediatrics. 1998 Feb;29(1):51-3
pubmed: 9553952
J Inherit Metab Dis. 1993;16(2):415-24
pubmed: 8412002
Adv Exp Med Biol. 2000;486:75-8
pubmed: 11783531
Mol Genet Metab Rep. 2020 May 06;23:100592
pubmed: 32405461
Radiol Case Rep. 2018 Nov 22;14(2):255-259
pubmed: 30510607
J Inherit Metab Dis. 1993;16(2):425-34
pubmed: 8412003
Brain Dev. 2007 Oct;29(9):600-2
pubmed: 17485188
J Pediatr. 2007 Jan;150(1):57-61.e2
pubmed: 17188615
Nat Genet. 1992 Apr;1(1):59-63
pubmed: 1302001